Canton Strategic Holdings (CNTN) Net Equity Issued and Repurchased (2022 - 2025)

Canton Strategic Holdings (CNTN) posted Net Equity Issued and Repurchased of $99.1 million for Q4 2025, up 893.89% on a QoQ basis from $10.0 million in Q4 2023.

Canton Strategic Holdings (CNTN) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends

Canton Strategic Holdings' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $99.1 million for Q4 2025.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $99.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $108.7 million (changed N/A YoY) and the FY2025 annual result came in at $99.4 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased was $99.1 million for Q4 2025 at Canton Strategic Holdings, up from $10.0 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $99.1 million in Q4 2025 and bottomed at -$386174.0 in Q3 2023.
  • A 3-year average of $30.6 million and a median of $11.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 141.90 Mn
10 Canton Strategic Holdings 425.80 Mn 425.80 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 99.10 Mn
Dec 31, 2025 99.10 Mn
Dec 31, 2023 9.97 Mn
Dec 31, 2023 9.97 Mn
Sep 30, 2023 -386,174.00
Sep 30, 2023 -386,174.00
Mar 31, 2022 13.65 Mn
Mar 31, 2022 13.65 Mn